ACTUALITES

SEMINARS

  • CRCL/CLB Seminar

The next CRCL/CLB seminar will take place Friday the 2nd of June, at 11.30am in the ONCORA meeting room (Centre Léon Bérard, 2nd floor). We are pleased to welcome Véronique BRAUD (Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis). Her talk will focus on: "Functions of innate immune cells during epithelial inflammation and cancer development".

SCIENTIFIC EVENTS

  • 3rd International Symposium of the CRCL

The 3rd CRCL Symposium will welcome you on the 25th-27th September 2017 ! Registration is now open and abstract submission is possible until the end of May.
More information on our website available 
here.

An overview of the 2015 edition 2015 can be found below:

OTHER

  • Junior group leader position

The Laboratory of Excellence (LabEx) DEVweCAN invites applications for a Junior Group leader position in immunology in Research Institutions of Lyon.

More informations: click here

LATEST PUBLICATIONS

  • A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability

Morel AP et al. Nature Medecine Avril 2017. The work presented in this publication was conducted by the of Alain Puisieux and his partners.

Chromosomal instability (CIN), a feature of most adult neoplasms from their early stages onward, is a driver of tumorigenesis. However, several malignancy subtypes, including some triple-negative breast cancers, display a paucity of genomic aberrations, thus suggesting that tumor development may occur in the absence of CIN. Here we show that the differentiation status of normal human mammary epithelial cells dictates cell behavior after an oncogenic event and predetermines the genetic routes toward malignancy. Whereas oncogene induction in differentiated cells induces massive DNA damage, mammary stem cells are resistant, owing to a preemptive program driven by the transcription factor ZEB1 and the methionine sulfoxide reductase MSRB3. The prevention of oncogene-induced DNA damage precludes induction of the oncosuppressive p53-dependent DNA-damage response, thereby increasing stem cells' intrinsic susceptibility to malignant transformation. In accord with this model, a subclass of breast neoplasms exhibit unique pathological features, including high ZEB1 expression, a low frequency of TP53 mutations and low CIN.
PubMed access: click here


  • A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability

This study involves the team of Patrick Mehlen. 
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.

PubMed access: click here

JOB OPPORTUNITIES

  • Mars 2017

Un poste de technicien de laboratoire est à pourvoir dans le groupe de F.tirode
Plus d'informations ici

  • Janvier 2017
A 2 Years postdoc position open in tumour immunology.
More information here

 

  • Février 2017
A postdoc position in onco-immunology is available in C. Caux's lab
More information here

 

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :